Engineered pH-dependent recycling antibodies enhance elimination of Staphylococcal enterotoxin B superantigen in mice

References

• Marshall MJE, Stopforth RJ, Cragg MS. Therapeutic antibodies: what have we learnt from targeting CD20 and where are we going? Front Immunol. 2017;8:1245. doi:10.3389/fimmu.2017.01245.
   PubMed Web of Science ®Google Scholar
• Kennedy PJ, Oliveira C, Granja PL, Sarmento B. Monoclonal antibodies: technologies for early discovery and engineering. Crit Rev Biotechnol. 2018;38:394–408. doi:10.1080/07388551.2017.1357002.
   PubMed Web of Science ®Google Scholar
• Singh S, Kumar NK, Dwiwedi P, Charan J, Kaur R, Sidhu P, Chugh VK. Monoclonal Antibodies: A Review. Curr Clin Pharmacol 2018;13:85-99.
   Google Scholar
• Chames P, Van Regenmortel M, Weiss E, Baty D. Therapeutic antibodies: successes, limitations and hopes for the future. Br J Pharmacol. 2009;157:220–233. doi:10.1111/j.1476-5381.2009.00190.x.
   PubMed Web of Science ®Google Scholar
• Igawa T, Ishii S, Tachibana T, Maeda A, Higuchi Y, Shimaoka S, Moriyama C, Watanabe T, Takubo R, Doi Y, et al. Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization. Nat Biotechnol 2010; 28:1203-7.
   Google Scholar
• Schroter C, Gunther R, Rhiel L, Becker S, Toleikis L, Doerner A, Becker J, Schönemann A, Nasu D, Neuteboom B, et al. A generic approach to engineer antibody pH-switches using combinatorial histidine scanning libraries and yeast display. mAbs. 2015;7:138–151. doi:10.4161/19420862.2014.985993.
   PubMed Web of Science ®Google Scholar
• Bonvin P, Venet S, Fontaine G, Ravn U, Gueneau F, Kosco-Vilbois M, Proudfoot AE, Fischer N. De novo isolation of antibodies with pH-dependent binding properties. mAbs. 2015;7:294–302. doi:10.1080/19420862.2015.1006993.
   PubMed Web of Science ®Google Scholar
• Hu YB, Dammer EB, Ren RJ, Wang G. The endosomal-lysosomal system: from acidification and cargo sorting to neurodegeneration. Transl Neurodegener. 2015;4:18. doi:10.1186/s40035-015-0041-1.
   PubMed Web of Science ®Google Scholar
• Chaparro-Riggers J, Liang H, DeVay RM, Bai L, Sutton JE, Chen W, Geng T, Lindquist K, Casas MG, Boustany LM, et al. Increasing serum half-life and extending cholesterol lowering in vivo by engineering antibody with pH-sensitive binding to PCSK9. J Biol Chem. 2012;287:11090–11097. doi:10.1074/jbc.M111.319764.
   PubMed Web of Science ®Google Scholar
• Devanaboyina SC, Lynch SM, Ober RJ, Ram S, Kim D, Puig-Canto A, Breen S, Kasturirangan S, Fowler S, Peng L, et al. The effect of pH dependence of antibody-antigen interactions on subcellular trafficking dynamics. mAbs. 2013;5:851–859. doi:10.4161/mabs.26389.
   PubMed Web of Science ®Google Scholar
• Dutta K, Varshney AK, Franklin MC, Goger M, Wang X, Fries BC. Mechanisms mediating enhanced neutralization efficacy of staphylococcal enterotoxin B by combinations of monoclonal antibodies. J Biol Chem. 2015;290:6715–6730. doi:10.1074/jbc.M114.630715.
   PubMed Web of Science ®Google Scholar
• Karauzum H, Chen G, Abaandou L, Mahmoudieh M, Boroun AR, Shulenin S, Devi VS, Stavale E, Warfield KL, Zeitlin L, et al. Synthetic human monoclonal antibodies toward staphylococcal enterotoxin B (SEB) protective against toxic shock syndrome. J Biol Chem. 2012;287:25203–25215. doi:10.1074/jbc.M112.364075.
   PubMed Web of Science ®Google Scholar
• Kong C, Neoh HM, Nathan S. Targeting staphylococcus aureus toxins: a potential form of anti-virulence therapy. Toxins (Basel). 2016;8. doi:10.3390/toxins8030072.
   PubMed Web of Science ®Google Scholar
• Xia T, Liang S, Wang H, Hu S, Sun Y, Yu X, Han J, Li J, Guo S, Dai J, et al. Structural basis for the neutralization and specificity of Staphylococcal enterotoxin B against its MHC Class II binding site. mAbs. 2014;6:119–129. doi:10.4161/mabs.27106.
   PubMed Web of Science ®Google Scholar
• Varshney AK, Wang X, Scharff MD, MacIntyre J, Zollner RS, Kovalenko OV, Martinez LR, Byrne FR, Fries BC. Staphylococcal enterotoxin B-specific monoclonal antibody 20B1 successfully treats diverse Staphylococcus aureus infections. J Infect Dis. 2013;208:2058–2066. doi:10.1093/infdis/jit421.
   PubMed Web of Science ®Google Scholar
• Drozdowski B, Zhou Y, Kline B, Spidel J, Chan YY, Albone E, Turchin H, Chao Q, Henry M, Balogach J, et al. Generation and characterization of high affinity human monoclonal antibodies that neutralize staphylococcal enterotoxin B. J Immune Based Ther Vaccines. 2010;8:9. doi:10.1186/1476-8518-8-9.
   PubMedGoogle Scholar
• Larkin EA, Stiles BG, Ulrich RG. Inhibition of toxic shock by human monoclonal antibodies against staphylococcal enterotoxin B. PLoS One. 2010;5:e13253. doi:10.1371/journal.pone.0013253.
   PubMed Web of Science ®Google Scholar
• Varshney AK, Wang X, Cook E, Dutta K, Scharff MD, Goger MJ, Fries BC. Generation, characterization, and epitope mapping of neutralizing and protective monoclonal antibodies against staphylococcal enterotoxin B-induced lethal shock. J Biol Chem. 2011;286:9737–9747. doi:10.1074/jbc.M110.212407.
   PubMed Web of Science ®Google Scholar
• Boles JW, Pitt ML, LeClaire RD, Gibbs PH, Torres E, Dyas B, Ulrich RG, Bavari S. Generation of protective immunity by inactivated recombinant staphylococcal enterotoxin B vaccine in nonhuman primates and identification of correlates of immunity. Clin Immunol. 2003;108:51–59.
   PubMed Web of Science ®Google Scholar
• Asensi GF, de Sales NF, Dutra FF, Feijo DF, Bozza MT, Ulrich RG, Miyoshi A, de Morais K, Azevedo VADC, Silva JT, et al. Oral immunization with Lactococcus lactis secreting attenuated recombinant staphylococcal enterotoxin B induces a protective immune response in a murine model. Microb Cell Fact. 2013;12:32. doi:10.1186/1475-2859-12-32.
   PubMed Web of Science ®Google Scholar
• Scherrmann J-M. Antibody treatment of toxin poisoning recent advances. J Toxicol. 1994;32:363–375.
   PubMed Web of Science ®Google Scholar
• Pepper LR, Cho YK, Boder ET, Shusta EV. A decade of yeast surface display technology: where are we now? Comb Chem High Throughput Screen. 2008;11:127–134.
   PubMed Web of Science ®Google Scholar
• Zaccolo M, Gherardi E. The effect of high-frequency random mutagenesis on in vitro protein evolution: a study on TEM-1 beta-lactamase. J Mol Biol. 1999;285:775–783. doi:10.1006/jmbi.1998.2262.
   PubMed Web of Science ®Google Scholar
• Huotari J, Helenius A. Endosome maturation. Embo J. 2011;30:3481–3500. doi:10.1038/emboj.2011.286.
   PubMed Web of Science ®Google Scholar
• Thilo L, Stroud E, Haylett T. Maturation of early endosomes and vesicular traffic to lysosomes in relation to membrane recycling. J Cell Sci. 1995;108(Pt 4):1791–1803.
   PubMed Web of Science ®Google Scholar
• Shusta EV, Kieke MC, Parke E, Kranz DM, Wittrup KD. Yeast polypeptide fusion surface display levels predict thermal stability and soluble secretion efficiency. J Mol Biol. 1999;292:949–956. doi:10.1006/jmbi.1999.3130.
   PubMed Web of Science ®Google Scholar
• Killikelly A, Zhang HT, Spurrier B, Williams C, Gorny MK, Zolla-Pazner S, Kong X-P. Thermodynamic signatures of the antigen binding site of mAb 447-52D targeting the third variable region of HIV-1 gp120. Biochemistry. 2013;52:6249–6257. doi:10.1021/bi400645e.
   PubMed Web of Science ®Google Scholar
• Bostrom J, Haber L, Koenig P, Kelley RF, Fuh G. High affinity antigen recognition of the dual specific variants of herceptin is entropy-driven in spite of structural plasticity. PLoS One. 2011;6:e17887. doi:10.1371/journal.pone.0017887.
   PubMed Web of Science ®Google Scholar
• Chakraborty A, Van LM, Skerjanec A, Floch D, Klein UR, Krammer G, Sunkara G, Howard D. Pharmacokinetic and pharmacodynamic properties of canakinumab in patients with gouty arthritis. J Clin Pharmacol. 2013;53:1240–1251. doi:10.1002/jcph.162.
   PubMed Web of Science ®Google Scholar
• Fetterly GJ, Aras U, Meholick PD, Takimoto C, Seetharam S, McIntosh T, de Bono JS, Sandhu SK, Tolcher A, Davis HM, et al. Utilizing pharmacokinetics/pharmacodynamics modeling to simultaneously examine free CCL2, total CCL2 and carlumab (CNTO 888) concentration time data. J Clin Pharmacol. 2013;53:1020–1027. doi:10.1002/jcph.140.
   PubMed Web of Science ®Google Scholar
• Siemers ER, Friedrich S, Dean RA, Gonzales CR, Farlow MR, Paul SM, Demattos RB. Safety and changes in plasma and cerebrospinal fluid amyloid beta after a single administration of an amyloid beta monoclonal antibody in subjects with Alzheimer disease. Clin Neuropharmacol. 2010;33:67–73. doi:10.1097/WNF.0b013e3181cb577a.
   PubMed Web of Science ®Google Scholar
• Xiao JJ, Krzyzanski W, Wang YM, Li HY, Rose MJ, Ma M, Wu Y, Hinkle B, Perez-Ruixo JJ. Pharmacokinetics of anti-hepcidin monoclonal antibody Ab 12B9m and hepcidin in cynomolgus monkeys. Aaps J. 2010;12:646–657. doi:10.1208/s12248-010-9222-0.
   PubMed Web of Science ®Google Scholar
• Varshney AK, Wang X, Aguilar JL, Scharff MD, Fries BC. Isotype switching increases efficacy of antibody protection against staphylococcal enterotoxin B-induced lethal shock and Staphylococcus aureus sepsis in mice. MBio. 2014;5:e01007–14. doi:10.1128/mBio.01007-14.
   PubMed Web of Science ®Google Scholar
• Fraser JD. Clarifying the mechanism of superantigen toxicity. PLoS Biol. 2011;9:e1001145. doi:10.1371/journal.pbio.1001145.
   PubMed Web of Science ®Google Scholar
• Fries BC, Varshney AK. Bacterial Toxins-Staphylococcal Enterotoxin B. Microbiol Spectr 2013;1:1-12.
   Google Scholar
• VanAntwerp JJ, Wittrup KD. Fine affinity discrimination by yeast surface display and flow cytometry. Biotechnol Prog. 2000;16:31–37. doi:10.1021/bp990133s.
   PubMed Web of Science ®Google Scholar
• Fellouse FA, Barthelemy PA, Kelley RF, Sidhu SS. Tyrosine plays a dominant functional role in the paratope of a synthetic antibody derived from a four amino acid code. J Mol Biol. 2006;357:100–114. doi:10.1016/j.jmb.2005.11.092.
   PubMed Web of Science ®Google Scholar
• Heinrich L, Tissot N, Hartmann DJ, Cohen R. Comparison of the results obtained by ELISA and surface plasmon resonance for the determination of antibody affinity. J Immunol Methods. 2010;352:13–22. doi:10.1016/j.jim.2009.10.002.
   PubMed Web of Science ®Google Scholar
• Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol. 2007;7:715–725. doi:10.1038/nri2155.
   PubMed Web of Science ®Google Scholar
• Yang D, Giragossian C, Castellano S, Lasaro M, Xiao H, Saraf H, Hess Kenny C, Rybina I, Huang Z-F, Ahlberg J, et al. Maximizing in vivo target clearance by design of pH-dependent target binding antibodies with altered affinity to FcRn. mAbs. 2017;9:1105–1117. doi:10.1080/19420862.2017.1359455.
   PubMed Web of Science ®Google Scholar
• Boder ET, Wittrup KD. Yeast surface display for screening combinatorial polypeptide libraries. Nat Biotechnol. 1997;15:553–557. doi:10.1038/nbt0697-553.
   PubMed Web of Science ®Google Scholar
• Chao G, Lau WL, Hackel BJ, Sazinsky SL, Lippow SM, Wittrup KD. Isolating and engineering human antibodies using yeast surface display. Nat Protoc. 2006;1:755–768. doi:10.1038/nprot.2006.94.
   PubMed Web of Science ®Google Scholar